News
Why Vertex Pharmaceuticals Stock Is Sinking Today
Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) were sinking 11.9% as of 10:18 a.m. ET on Tuesday. Vertex reported Q1 revenue of $2.77 billion, up 3% year over year. In addition, Vertex revealed that it has temporarily paused the multiple ascending dose portion of its phase 1/2 study evaluating experimental messenger RNA (mRNA) therapy VX-522 in treating cystic fibrosis (CF).
Vertex Pharmaceuticals sees brighter prospects despite Q1 misses, with promising launches, pipeline progress, and upgraded ...
VRTX has recorded a positive one-day return after earnings in 58% of instances. When the return is positive, the median ...
Vertex Pharmaceuticals is pressing pause on a phase 1/2 cystic fibrosis (CF) trial over a tolerability issue, while reporting ...
Vertex Pharmaceuticals reports first-quarter financial results after the market close on Monday. Here's a look at the key highlights from the period.
Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback